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tables. A comparative CE model, incorporating fondaparinux,
was developed. Incremental cost-effectiveness ratios (ICERs)
were calculated. Since no fondaparinux was used, we applied
rates from published trials, and adjusted for the mean propor-
tional increase in rates between 49 days (trial follow-up) and
one year in Veterans. For fondaparinux, costs were estimated
from mean costs of complications among the other TSs, with an
adjustment for increased medication cost. One-way sensitivity
analyses (SA) were performed by incorporating the mean prob-
abilities of DVT among each other TSs into the least-costly TS
or decreasing the costs of complication arms by one standard
deviation. RESULTS: There were 3037 patients, 131 VTEs, and
53 deaths. Dalteparin was dominant; the least-costly per patient
with fewest VTEs ($16,310, 1.0%) compared to warfarin
($17,803, 3.5%), enoxaparin ($19,253, 2.4%), enoxaparin/
warfarin ($23,641, 22.7%), and fondaparinux ($19,577, 1.6%).
Thus, ICERS indicated more costs and more events with other
TSs. Deaths occurred in 2% of dalteparin patients, thus ICERS
for LYG (deaths) were warfarin $27,004 (1.7%), enoxaparin
$33,232 (1.5%), enoxaparin/warfarin $40,479 (1.1%), and
fondaparinux $20,355 (estimated 1.2%). Each SA showed dalte-
parin remained the least-costly TS per VTE avoided. CONCLU-
SION: Dalteparin was the least-costly TS and had the fewest
VTEs.
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OBJECTIVE: The objective of this study was to compare the
cost-effectiveness of tension-free mesh and tension suture
methods of inguinal hernia repair in Hungary, from hospital and
payer perspectives. METHODS: Cost effectiveness of open mesh
vs. open non mesh was modeled with a Cohort Markov model.
Model simulation runs in yearly cycles up to 15 years. Transition
probabilities were derived from systematic review and other pub-
lished sources. Costs were collected from two hospitals and from
the payer in Hungary. Utility values were extracted from the
published sources. Both costs and outcomes were discounted
annually at 5%. In probabilistic sensitive analysis simulations
were repeated 10,000 times. CEAC curves were generated as a
result of simulation for all scenarios. RESULTS: Over a 5 and 15
year period open mesh provides greater beneﬁts in terms of more
QALYs and fewer recurrences at a cumulatively higher cost than
open non mesh procedures. Cost per one additional QALY is
€13,221 in a 5 years time horizon and €2819 in a 15 years time
horizon from a payer perspective. Cost per one recurrence
avoided is €885 in a 5 years time horizon and €173 in a 15 years
time horizon from payer perspective. When the costs from a
hospital perspective are used the open mesh option is the domi-
nant technology over the open non mesh option. Results in the
probability sensitivity analysis are very similar to deterministic
analysis. In the ﬁve year perspective open mesh is the more cost
effective option in comparison to open non mesh option when
the value for society’s willingness to pay for a QALY exceeds
€6000 (€700 in the 15 years perspective). CONCLUSION: Find-
ings suggest open mesh hernia repair method as a very cost
effective therapy from both hospitals and payer perspectives for
the inguinal hernia treatment in Hungary.
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OBJECTIVE: To compare the cost-effectiveness of tension-free
mesh and tension suture methods of inguinal hernia repair in
Poland, from hospital and payer perspectives. METHODS: Cost
effectiveness of open mesh vs open non mesh was modeled with
a Cohort Markov model. Model simulation runs in yearly cycles
up to 15 years. Transition probabilities were derived from sys-
tematic review and other published sources. Costs were collected
from four hospitals and from the payer in Poland. Utility values
were extracted from the published sources. Both costs and out-
comes were discounted annually at 5%. In probabilistic sensitive
analysis simulations were repeated 10,000 times. CEAC curves
were generated as a result of simulation for all scenarios.
RESULTS: Over a 5 and 15 year period open mesh provides
greater beneﬁts in terms of more QALYs and fewer recurrences at
a cumulatively higher cost than open non mesh. The cost per one
additional QALY is €16,730 in a 5 years time horizon and €3236
in a 15 years time horizon from a payer perspective (€16,485 and
€3061 respectively from a hospital perspective). Cost per one
recurrence avoided is €1096 in a 5 years time horizon and €199
in a ﬁfteen years time horizon from a payer perspective (€1103
and €188 respectively from hospital perspective). Results from
the probability sensitivity analysis are very similar to determin-
istic analyses. In the ﬁve year perspective open mesh is more
cost effective in comparison to the open non mesh option when
the value for society’s willingness to pay for a QALY exceeds
€10,000 (€500 in the 15 years perspective). CONCLUSION:
Findings suggest open mesh hernia repair method as a very cost
effective therapy from both hospitals and payer perspectives for
the inguinal hernia treatment in Poland.
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OBJECTIVE: The objective of this study was to compare the
cost-effectiveness of tension-free mesh and tension suture
methods of inguinal hernia repair in Slovakia, from hospital and
the payer perspective. METHODS: Cost effectiveness of open
mesh vs open non mesh was modeled with a Cohort Markov
model. Model simulation runs in yearly cycles up to 15 years.
Transition probabilities were derived from systematic review and
other published sources. Costs were collected from two hospitals
and from the payer in Slovakia. Utility values were extracted
from the published sources. Both costs and outcomes were dis-
counted annually at 5%. In probabilistic sensitive analysis simu-
lations were repeated 10,000 times. CEAC curves were generated
as a result of simulation for all scenarios. RESULTS: Over a 5
and 15 year period open mesh provides greater beneﬁts in terms
of more QALYs and fewer recurrences than open non-mesh.
When the costs from a payer’s perspective are used the open
mesh option is the dominant technology over open non mesh
option (equal payment for open mesh and open non mesh
options). The cost per one additional QALY is €1230 in a 5 years
time horizon and the open mesh is the cost effective option in a
15 years time horizon from a hospital perspective. Cost per one
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recurrence avoided is €82 in the 5 years time horizon and the
open mesh is the dominant option in the 15 years time horizon
from a hospital perspective. Results in the probability sensitivity
analysis are very similar to deterministic analysis. CONCLU-
SION: Findings suggest open mesh hernia repair method as a
very cost effective therapy from both hospitals and payers per-
spectives for the inguinal hernia treatment in Slovakia.
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OBJECTIVE: Operating rooms (OR) are an expensive hospital
resource. As a new selective reversal binding agent, sugammadex
has been shown in clinical trials to reduce reversal time (time
from reversal agent administration to full recovery) among
patients receiving selected steroidal neuromuscular-blocking
agents (NMBAs). Our goal was to develop a hospital efﬁciency
model to assess the potential impact of sugammadex adoption on
OR time. METHODS: A deterministic model was developed to
estimate potential time savings associated with sugammadex
adoption for the U.S. setting. Model inputs included surgical
caseloads, utilization rates of NMBAs and reversal strategies, OR
time components, and OR labor costs. The effects of reversal
strategies on reversal time were evaluated using clinical trial data.
Other model inputs were estimated using published literature
and analyses of secondary hospital databases. OR time saved was
deﬁned as the difference in minutes required for all procedures
performed per day in one OR before and after the introduction of
sugammadex. Estimates of savings in OR staff costs (including
OR nurse, OR technician, and certiﬁed registered nurse anesthe-
tist) were generated under alternative assumptions about the
likelihood that overtime is paid. Sensitivity analyses were per-
formed on key model assumptions. RESULTS: In the base-case
scenario, OR time saved by sugammadex was estimated to be
25 minutes per OR day or 612 hours annually in a typical US
hospital with 6 ORs. Associated annual cost savings were esti-
mated to range from $32,035 (25% of days involve overtime) to
$96,105 (75% of days involve overtime). Findings also varied
with the assumed adoption rate of sugammadex and hourly OR
staff salaries. CONCLUSION: Sugammadex may save OR time
and associated costs for U.S. hospitals, primarily by reducing
overtime pay. The net ﬁnancial beneﬁt of sugammadex will
depend on its cost and its adoption rate in clinical practice.
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OBJECTIVE: Deep vein thrombosis (DVT) and pulmonary
embolism (PE), collectively known as venous thromboembolism
(VTE), are well-known complications of total knee or hip
arthroplasty (TKA and THA). This study examined the eco-
nomic burden of VTE in arthroplasty surgeries from a US hos-
pital perspective. METHODS: Patients at least 18 years old
undergoing TKA and THA from January 1, 2002 to December
30, 2006 were extracted from a large, nationwide inpatient
database. Rates of events, length of hospital stay, inpatient costs
and reimbursed amounts (available for a small subset that could
be linked to managed care data) were evaluated. Multivariate
analyses were conducted on hospital costs to adjust for differ-
ences in demographic and clinical characteristics. RESULTS:
Out of 259,524 hip and knee surgeries (mean age of 67 years),
1.0% of patients diagnosed with VTE during hospitalization
(0.6% DVT only and 0.4% PE [with or without DVT]). Com-
pared to patients without VTE, mean length of stay (LOS) for
those with VTE was twice as long (8 vs. 4, p < 0.0001) and
hospital costs were 48.0% higher ($20,850 vs. $14,092,
p < 0.0001). Within the limited subset that had linked managed
care claims data (n = 5002), mean cost of patients with VTE
was 23.5% higher ($16,877 vs. $13,662, p < 0.0023); however,
the amount reimbursed was on average 6.4% higher ($14,121
vs. $13,272, p = 0.77). After multivariate adjustment, DVT
increased costs by $1421 following TKA and $3950 following
THA; PE increased costs by $2862 following TKA and $4355
following THA (p < 0.0001 for all). CONCLUSION: Experi-
encing VTE complications substantially adds to the costs of
TKA or THA. The increased hospital costs of patients with VTE
did not appear to be adequately reimbursed. The overall eco-
nomic impact of implementing prophylaxis to prevent VTE
events can be projected.
HEALTH CARE INTERVENTIONS—
Patient-Reported Outcomes
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OBJECTIVE: The objective of this project was to review pub-
lished studies on quality of life (QoL) in animals. METHODS:
An electronic search in EMBASE including MEDLINE using
the key words “quality of life” and “animals” resulted in 1588
articles. Inclusion criteria for review was study on QoL, exclu-
sion criteria were case studies with n < 3, and studies in labora-
tory animals as proxy for humans. RESULTS: A total of 48
studies were included for review, of which 40 were performed in
dogs. The aim of nine studies was the development and valida-
tion of a questionnaire, three studies provided a checklist or
background information on QoL in animals. In the remaining 36
studies QoL was assessed as outcome measure in speciﬁc diseases
or treatments; however 30 of these studies were uncontrolled.
Previously developed, used or validated questionnaires were
included in only 3 studies. In 23 studies assessment of QoL was
limited to one single question, addressed to the owners. In 30 of
the 36 studies the evaluation of QoL was performed only at one
time point after the start of an intervention, of which 3 studies
retrospectively evaluated a baseline value. In 19 studies, all or
part of the animals were already dead at the time of assessment.
In 19 of the 30 uncontrolled studies QoL was rated as good to
excellent (or equivalent in scores) in >50% of the animals, even
in studies on severe conditions such as cancer or chemotherapy.
CONCLUSION: Most of the studies assessing QoL as outcome
used unvalidated questionnaires and included only one single
question addressed to the owners. It is questionable whether the
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